Chemotherapy with hybrid liposomes for melanomatosis.
The inhibitory effects of the hybrid liposomes on the growth of B-16 melanoma cells in vitro and in vivo were examined. The 50% inhibitory concentration of the hybrid liposomes composed of 90 mol% dimyristoylphosphatidylcholine (DMPC) and 10 mol% polyoxyethylenedodecyl ether (C12(EO)10) was one-twelfth of that of DMPC liposomes. It was noteworthy that for the first time significantly prolonged survival was obtained using a mouce model of carcinoma after the administration of the hybrid liposomes of 90 mol% DMPC/10 mol% C12(EO)n (n=10 or 23) without antitumor drugs.
Kanno
A
A
Graduate Course of Applied Chemistry, Kumamoto Institute of Technology, Japan.
Tsuzaki
K
K
Miyagi
M
M
Matsumoto
Y
Y
Ueoka
R
R
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004134:Dimyristoylphosphatidylcholine / Q000494:pharmacology / Q000627:therapeutic use*; D004354:Drug Screening Assays, Antitumor; D008081:Liposomes / Q000494:pharmacology* / Q000627:therapeutic use; D008546:Melanoma, Experimental / Q000188:drug therapy*; D051379:Mice; D009368:Neoplasm Transplantation; D000077423:Polidocanol; D011092:Polyethylene Glycols / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D008081:Liposomes; D000077423:Polidocanol; D011092:Polyethylene Glycols; D004134:Dimyristoylphosphatidylcholine